Literature DB >> 26333409

Cancer research in need of a scientific revolution: Using 'paradigm shift' as a method of investigation.

Didier Wion1, Florence Appaix, Meriwether Burruss, Francois Berger, Boudewijn van der Sanden.   

Abstract

Despite important human and financial resources and considerable accumulation of scientific publications, patents, and clinical trials, cancer research has been slow in achieving a therapeutic revolution similar to the one that occurred in the last century for infectious diseases. It has been proposed that science proceeds not only by accumulating data but also through paradigm shifts. Here, we propose to use the concept of 'paradigm shift' as a method of investigation when dominant paradigms fail to achieve their promises. The first step in using the 'paradigm shift' method in cancer research requires identifying its founding paradigms. In this review, two of these founding paradigms will be discussed: (i) the reification of cancer as a tumour mass and (ii) the translation of the concepts issued from infectious disease in cancer research. We show how these founding paradigms can generate biases that lead to over-diagnosis and over-treatment and also hamper the development of curative cancer therapies. We apply the 'paradigm shift' method to produce perspective reversals consistent with current experimental evidence. The 'paradigm shift' method enlightens the existence of a tumour physiologic-prophylactic-pathologic continuum. It integrates the target/antitarget concept and that cancer is also an extracellular disease. The 'paradigm shift' method has immediate implications for cancer prevention and therapy. It could be a general method of investigation for other diseases awaiting therapy.

Entities:  

Mesh:

Year:  2015        PMID: 26333409     DOI: 10.1007/s12038-015-9543-3

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  81 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 2.  Mechanosensitivity and compositional dynamics of cell-matrix adhesions.

Authors:  Herbert B Schiller; Reinhard Fässler
Journal:  EMBO Rep       Date:  2013-05-17       Impact factor: 8.807

Review 3.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

4.  Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.

Authors:  S Gately; P Twardowski; M S Stack; M Patrick; L Boggio; D L Cundiff; H W Schnaper; L Madison; O Volpert; N Bouck; J Enghild; H C Kwaan; G A Soff
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

5.  Quantifying the benefits and harms of screening mammography.

Authors:  H Gilbert Welch; Honor J Passow
Journal:  JAMA Intern Med       Date:  2014-03       Impact factor: 21.873

6.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 7.  Therapeutic targeting of tumor-stroma interactions.

Authors:  Stephen Hiscox; Peter Barrett-Lee; Robert I Nicholson
Journal:  Expert Opin Ther Targets       Date:  2011-03-10       Impact factor: 6.902

8.  One hundred years of somatic mutation theory of carcinogenesis: is it time to switch?

Authors:  Ana M Soto; Carlos Sonnenschein
Journal:  Bioessays       Date:  2014-01       Impact factor: 4.345

Review 9.  Can cancer be reversed by engineering the tumor microenvironment?

Authors:  Donald E Ingber
Journal:  Semin Cancer Biol       Date:  2008-04-01       Impact factor: 15.707

Review 10.  Targeting the tumor stroma as a novel therapeutic approach for prostate cancer.

Authors:  Omar E Franco; Simon W Hayward
Journal:  Adv Pharmacol       Date:  2012
View more
  2 in total

1.  Glioma resection and tumor recurrence: back to Semmelweis.

Authors:  David Ratel; Boudewijn van der Sanden; Didier Wion
Journal:  Neuro Oncol       Date:  2016-10-07       Impact factor: 12.300

Review 2.  A Tumor Profile in Primary Immune Deficiencies Challenges the Cancer Immune Surveillance Concept.

Authors:  Daniel Satgé
Journal:  Front Immunol       Date:  2018-05-24       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.